

## Bausch Health Launches YUN Probiotherapy™ ACN Skincare Line in Poland

September 01, 2025

New probiotic and prebiotic skincare products offer a natural and effective solution for managing acne-prone skin.

- **Following the partnership announcement with YUN NV, Bausch Health has introduced the YUN ACN skincare line in Poland, featuring probiotic and prebiotic formulations designed for acne-prone skin.**
- **The product range includes YUN ACN Repair Cream, Wash gel, and Micellar water, all supporting the skin's natural microbiome without the drawbacks of traditional acne treatments.**
- **Recent scientific research demonstrates that incorporating probiotics into skincare significantly reduces pimples without side effects<sup>1</sup>, offering a natural and innovative alternative.**

LAVAL, QC, September 1, 2025 – Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the launch of the YUN ACN skincare line in Poland, offering probiotic and prebiotic formulations designed for acne-prone skin. Following Bausch Health's partnership announcement with YUN NV last June, YUN Probiotherapy™ ACN products are now available in pharmacies across Poland. The skincare product range includes YUN ACN Repair Cream, Wash gel, and Micellar water, all supporting the skin's natural microbiome.

Building on the latest advancements in microbiome science, the YUN ACN line offers a suite of products tailored to support healthy skin. The YUN ACN Repair Cream is a probiotic face cream that helps restore the skin's natural microbiome balance and improves hydration. The YUN ACN Wash is a prebiotic cleansing gel that gently cleanses the skin and supports the skin's good bacteria, and the YUN ACN Micel is a prebiotic micellar cleaning water that effectively removes impurities.

"We are excited to bring the YUN ACN probiotherapeutical skincare line to the Polish market", said **Cees Heiman, Senior Vice President, Europe and Canada, Bausch Health**. "These next-generation dermatological products leverage groundbreaking microbiome science for natural and effective management of acne-prone skin. This launch underscores our dedication to bringing innovative, science-driven solutions to more people worldwide."

A recent study published in the scientific journal Cell Reports Medicine demonstrated the powerful effect of probiotics incorporated into a skin cream through microcapsules. The findings showed the skin cream with microcapsules containing probiotics significantly reduced pimples without any side effects. <sup>1</sup> The YUN ACN skincare line offers a safe and effective alternative to traditional acne treatments.

"At YUN, we embrace good bacteria to support healthy skin. Our novel microcapsule technology keeps these helpful bacteria alive in our ACN skincare products, helping to naturally reduce pimples and impurities. This groundbreaking method offers a safe alternative to traditional ones," explained **Ingmar Claes, Chief Scientific Officer, YUN NV**.

To learn more about the YUN ACN products available at select pharmacies across Poland, please visit

[yun-probiotherapy.com](http://yun-probiotherapy.com)

.

## Reference:

- Lebeer S, et al. Selective targeting of skin pathobionts and inflammation with topically applied lactobacilli. Cell Rep Med. 2022 Feb 15;3(2):100521. doi:10.1016/j.xcrm.2022.100521.

## About Bausch Health

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit

[www.bauschhealth.com](http://www.bauschhealth.com)

and connect with us on

[LinkedIn](#)

.

## About Yun NV

YUN is a Belgian biotech company redefining everyday care through microbiome science. Founded in 2016, YUN developed the patented YUN Probiotherapy™ platform, featuring live probiotics and microbiome-friendly formulations designed to respect and support the skin's natural balance. With innovations across dermatological, oral, baby, intimate, and ear care, YUN delivers science- and quality-driven, nature-powered solutions for health-conscious patients and consumers, today and for generations to come. For more information about YUN, visit

[www.yun-probiotherapy.com](http://www.yun-probiotherapy.com)

and connect with us on

[LinkedIn](#)

.

## Forward Looking Statements

This news release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements

to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

**Investor Contact:**

Garen Sarafian  
[ir@bauschhealth.com](mailto:ir@bauschhealth.com)

877-281-6642 (toll-free)

**Media Contact:**

Katie Savastano  
[corporate.communications@bauschhealth.com](mailto:corporate.communications@bauschhealth.com)

(908) 569-3692



**Investor Inquiries**

[ir@bauschhealth.com](mailto:ir@bauschhealth.com)

877-281-6642  
514-856-3855 (Canada)

**Media inquiries**

[Corporate.communications@bauschhealth.com](mailto:Corporate.communications@bauschhealth.com)  
908-569-3692

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.  
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

**CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION**